Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,580.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,316.0,1.0,=,1.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1454.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1399.0,1.0,=,1.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1582.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,779.0,1.0,=,2.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2180.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1082.0,1.0,=,2.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2340.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,457.0,1.0,=,5.1
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2881.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,2075.0,1.0,=,1.4
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3943.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1603.0,1.0,=,2.5
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,608.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,369.0,1.0,=,1.6
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,625.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,499.0,1.0,=,1.3
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,893.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,349.0,1.0,=,2.6
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,912.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,386.0,1.0,=,2.4
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1177.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,995.0,1.0,=,1.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1190.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,480.0,1.0,=,2.5
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1309.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,824.0,1.0,=,1.6
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2A,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1357.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,757.0,1.0,=,1.8